References analysis of the Wikipedia article "Drug design" in the English version

books.google.com (Global: 3^rd place; English: 3^rd place)

Ganellin CR, Jefferis R, Roberts SM (2013). "The small molecule drug discovery process — from target selection to candidate selection". Introduction to Biological and Small Molecule Drug Research and Development: theory and case studies. Elsevier. ISBN 9780123971760.

Hopkins AL (2011). "Chapter 25: Pharmacological space". In Wermuth CG (ed.). The Practice of Medicinal Chemistry (3 ed.). Academic Press. pp. 521–527. ISBN 978-0-12-374194-3.

Tropsha A (2010). "QSAR in Drug Discovery". In Reynolds CH, Merz KM, Ringe D (eds.). Drug Design: Structure- and Ligand-Based Approaches (1st ed.). Cambridge, UK: Cambridge University Press. pp. 151–164. ISBN 978-0521887236.

Gramatica P (2011). "Chapter 17: Modeling Chemicals in the Environment". In Gramatica P, Livingstone DJ, Davis AM (eds.). Drug Design Strategies: Quantitative Approaches. RSC Drug Discovery. Royal Society of Chemistry. p. 466. doi:10.1039/9781849733410-00458. ISBN 978-1849731669.

doi.org (Global: 2^nd place; English: 2^nd place)

Fosgerau K, Hoffmann T (January 2015). "Peptide therapeutics: current status and future directions". Drug Discovery Today. 20 (1): 122–128. doi:10.1016/j.drudis.2014.10.003. PMID 25450771.

Ciemny M, Kurcinski M, Kamel K, Kolinski A, Alam N, Schueler-Furman O, Kmiecik S (August 2018). "Protein-peptide docking: opportunities and challenges". Drug Discovery Today. 23 (8): 1530–1537. doi:10.1016/j.drudis.2018.05.006. PMID 29733895.

Shirai H, Prades C, Vita R, Marcatili P, Popovic B, Xu J, et al. (November 2014). "Antibody informatics for drug discovery". Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1844 (11): 2002–2015. doi:10.1016/j.bbapap.2014.07.006. PMID 25110827.

Tollenaere JP (April 1996). "The role of structure-based ligand design and molecular modelling in drug discovery". Pharmacy World & Science. 18 (2): 56–62. doi:10.1007/BF00579706. PMID 8739258. S2CID 21550508.

Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, et al. (July 2015). "An analysis of the attrition of drug candidates from four major pharmaceutical companies". Nature Reviews. Drug Discovery. 14 (7): 475–486. doi:10.1038/nrd4609. PMID 26091267. S2CID 25292436.

Yu H, Adedoyin A (September 2003). "ADME-Tox in drug discovery: integration of experimental and computational technologies". Drug Discovery Today. 8 (18): 852–861. doi:10.1016/S1359-6446(03)02828-9. PMID 12963322.

Dixon SJ, Stockwell BR (December 2009). "Identifying druggable disease-modifying gene products". Current Opinion in Chemical Biology. 13 (5–6): 549–555. doi:10.1016/j.cbpa.2009.08.003. PMC 2787993. PMID 19740696.

Imming P, Sinning C, Meyer A (October 2006). "Drugs, their targets and the nature and number of drug targets". Nature Reviews. Drug Discovery. 5 (10): 821–834. doi:10.1038/nrd2132. PMID 17016423. S2CID 8872470.

Anderson AC (September 2003). "The process of structure-based drug design". Chemistry & Biology. 10 (9): 787–797. doi:10.1016/j.chembiol.2003.09.002. PMID 14522049.

Recanatini M, Bottegoni G, Cavalli A (December 2004). "In silico antitarget screening". Drug Discovery Today: Technologies. 1 (3): 209–215. doi:10.1016/j.ddtec.2004.10.004. PMID 24981487.

Scomparin A, Polyak D, Krivitsky A, Satchi-Fainaro R (November 2015). "Achieving successful delivery of oligonucleotides--From physico-chemical characterization to in vivo evaluation". Biotechnology Advances. 33 (6 Pt 3): 1294–1309. doi:10.1016/j.biotechadv.2015.04.008. PMID 25916823.

Youssef M, Hitti C, Puppin Chaves Fulber J, Kamen AA (October 2023). "Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing". Biomolecules. 13 (10): 1497. doi:10.3390/biom13101497. PMC 10604719. PMID 37892179.

Sahin U, Karikó K, Türeci Ö (October 2014). "mRNA-based therapeutics--developing a new class of drugs". Nature Reviews. Drug Discovery. 13 (10): 759–780. doi:10.1038/nrd4278. PMID 25233993. S2CID 27454546.

Swinney DC, Lee JA (2020). "Recent advances in phenotypic drug discovery". F1000Research. 9: F1000 Faculty Rev–944. doi:10.12688/f1000research.25813.1. PMC 7431967. PMID 32850117.

Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M (August 2017). "Opportunities and challenges in phenotypic drug discovery: an industry perspective". Nature Reviews. Drug Discovery. 16 (8): 531–543. doi:10.1038/nrd.2017.111. PMID 28685762. S2CID 6180139.

Yuan Y, Pei J, Lai L (Dec 2013). "Binding site detection and druggability prediction of protein targets for structure-based drug design". Current Pharmaceutical Design. 19 (12): 2326–2333. doi:10.2174/1381612811319120019. PMID 23082974.

Rishton GM (January 2003). "Nonleadlikeness and leadlikeness in biochemical screening". Drug Discovery Today. 8 (2): 86–96. doi:10.1016/s1359644602025722. PMID 12565011.

Nicolaou CA, Brown N (September 2013). "Multi-objective optimization methods in drug design". Drug Discovery Today: Technologies. 10 (3): e427 – e435. doi:10.1016/j.ddtec.2013.02.001. PMID 24050140.

Ban TA (2006). "The role of serendipity in drug discovery". Dialogues in Clinical Neuroscience. 8 (3): 335–344. doi:10.31887/DCNS.2006.8.3/tban. PMC 3181823. PMID 17117615.

Ethiraj SK, Levinthal D (Sep 2004). "Bounded Rationality and the Search for Organizational Architecture: An Evolutionary Perspective on the Design of Organizations and Their Evolvability". Administrative Science Quarterly. 49 (3). Sage Publications, Inc. on behalf of the Johnson Graduate School of Management, Cornell University: 404–437. doi:10.2307/4131441. JSTOR 4131441. S2CID 142910916. SSRN 604123.

Lewis RA (2011). "Chapter 4: The Development of Molecular Modelling Programs: The Use and Limitations of Physical Models". In Gramatica P, Livingstone DJ, Davis AM (eds.). Drug Design Strategies: Quantitative Approaches. RSC Drug Discovery. Royal Society of Chemistry. pp. 88–107. doi:10.1039/9781849733410-00088. ISBN 978-1849731669.

de Azevedo WF, Dias R (December 2008). "Computational methods for calculation of ligand-binding affinity". Current Drug Targets. 9 (12): 1031–1039. doi:10.2174/138945008786949405. PMID 19128212.

Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, Corbley MJ, et al. (December 2003). "Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI)". Bioorganic & Medicinal Chemistry Letters. 13 (24): 4355–4359. doi:10.1016/j.bmcl.2003.09.028. PMID 14643325.

Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, et al. (June 2006). "An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression". Journal of Medicinal Chemistry. 49 (11): 3116–3135. doi:10.1021/jm0508641. PMID 16722631.

Liang S, Meroueh SO, Wang G, Qiu C, Zhou Y (May 2009). "Consensus scoring for enriching near-native structures from protein-protein docking decoys". Proteins. 75 (2): 397–403. doi:10.1002/prot.22252. PMC 2656599. PMID 18831053.

Oda A, Tsuchida K, Takakura T, Yamaotsu N, Hirono S (2006). "Comparison of consensus scoring strategies for evaluating computational models of protein-ligand complexes". Journal of Chemical Information and Modeling. 46 (1): 380–391. doi:10.1021/ci050283k. PMID 16426072.

Deng Z, Chuaqui C, Singh J (January 2004). "Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions". Journal of Medicinal Chemistry. 47 (2): 337–344. doi:10.1021/jm030331x. PMID 14711306.

Amari S, Aizawa M, Zhang J, Fukuzawa K, Mochizuki Y, Iwasawa Y, et al. (2006). "VISCANA: visualized cluster analysis of protein-ligand interaction based on the ab initio fragment molecular orbital method for virtual ligand screening". Journal of Chemical Information and Modeling. 46 (1): 221–230. doi:10.1021/ci050262q. PMID 16426058.

Klebe G (2000). "Recent developments in structure-based drug design". Journal of Molecular Medicine. 78 (5): 269–281. doi:10.1007/s001090000084. PMID 10954199. S2CID 21314020.

Wang R, Gao Y, Lai L (2000). "LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design". Journal of Molecular Modeling. 6 (7–8): 498–516. doi:10.1007/s0089400060498. S2CID 59482623.

Schneider G, Fechner U (August 2005). "Computer-based de novo design of drug-like molecules". Nature Reviews. Drug Discovery. 4 (8): 649–663. doi:10.1038/nrd1799. PMID 16056391. S2CID 2549851.

Jorgensen WL (March 2004). "The many roles of computation in drug discovery". Science. 303 (5665): 1813–1818. Bibcode:2004Sci...303.1813J. doi:10.1126/science.1096361. PMID 15031495. S2CID 1307935.

Leis S, Schneider S, Zacharias M (2010). "In silico prediction of binding sites on proteins". Current Medicinal Chemistry. 17 (15): 1550–1562. doi:10.2174/092986710790979944. PMID 20166931.

Warren GL, Warren SD (2011). "Chapter 16: Scoring Drug-Receptor Interactions". In Gramatica P, Livingstone DJ, Davis AM (eds.). Drug Design Strategies: Quantitative Approaches. RSC Drug Discovery. Royal Society of Chemistry. pp. 440–457. doi:10.1039/9781849733410-00440. ISBN 978-1849731669.

Böhm HJ (June 1994). "The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure". Journal of Computer-Aided Molecular Design. 8 (3): 243–256. Bibcode:1994JCAMD...8..243B. doi:10.1007/BF00126743. PMID 7964925. S2CID 2491616.

Liu J, Wang R (March 2015). "Classification of current scoring functions". Journal of Chemical Information and Modeling. 55 (3): 475–482. doi:10.1021/ci500731a. PMID 25647463.

Murcko MA (December 1995). "Computational methods to predict binding free energy in ligand-receptor complexes". Journal of Medicinal Chemistry. 38 (26): 4953–4967. doi:10.1021/jm00026a001. PMID 8544170.

Greer J, Erickson JW, Baldwin JJ, Varney MD (April 1994). "Application of the three-dimensional structures of protein target molecules in structure-based drug design". Journal of Medicinal Chemistry. 37 (8): 1035–1054. doi:10.1021/jm00034a001. PMID 8164249.

Capdeville R, Buchdunger E, Zimmermann J, Matter A (July 2002). "Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug". Nature Reviews. Drug Discovery. 1 (7): 493–502. doi:10.1038/nrd839. PMID 12120256. S2CID 2728341.

Prior M, Chiruta C, Currais A, Goldberg J, Ramsey J, Dargusch R, et al. (July 2014). "Back to the future with phenotypic screening". ACS Chemical Neuroscience. 5 (7): 503–513. doi:10.1021/cn500051h. PMC 4102969. PMID 24902068.

Kotz J (April 2012). "Phenotypic screening, take two". Science-Business EXchange. 5 (15): 380. doi:10.1038/scibx.2012.380. ISSN 1945-3477. S2CID 72519717.

Hertzberg RP, Pope AJ (August 2000). "High-throughput screening: new technology for the 21st century". Current Opinion in Chemical Biology. 4 (4): 445–451. doi:10.1016/S1367-5931(00)00110-1. PMID 10959774.

Walters WP, Stahl MT, Murcko MA (April 1998). "Virtual screening—an overview". Drug Discovery Today. 3 (4): 160–178. doi:10.1016/S1359-6446(97)01163-X.

Klein DF (March 2008). "The loss of serendipity in psychopharmacology". JAMA. 299 (9): 1063–1065. doi:10.1001/jama.299.9.1063. PMID 18319418.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Fosgerau K, Hoffmann T (January 2015). "Peptide therapeutics: current status and future directions". Drug Discovery Today. 20 (1): 122–128. doi:10.1016/j.drudis.2014.10.003. PMID 25450771.

Anderson AC (September 2003). "The process of structure-based drug design". Chemistry & Biology. 10 (9): 787–797. doi:10.1016/j.chembiol.2003.09.002. PMID 14522049.

Recanatini M, Bottegoni G, Cavalli A (December 2004). "In silico antitarget screening". Drug Discovery Today: Technologies. 1 (3): 209–215. doi:10.1016/j.ddtec.2004.10.004. PMID 24981487.

Swinney DC, Lee JA (2020). "Recent advances in phenotypic drug discovery". F1000Research. 9: F1000 Faculty Rev–944. doi:10.12688/f1000research.25813.1. PMC 7431967. PMID 32850117.

Rishton GM (January 2003). "Nonleadlikeness and leadlikeness in biochemical screening". Drug Discovery Today. 8 (2): 86–96. doi:10.1016/s1359644602025722. PMID 12565011.

Ban TA (2006). "The role of serendipity in drug discovery". Dialogues in Clinical Neuroscience. 8 (3): 335–344. doi:10.31887/DCNS.2006.8.3/tban. PMC 3181823. PMID 17117615.

Rajamani R, Good AC (May 2007). "Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development". Current Opinion in Drug Discovery & Development. 10 (3): 308–315. PMID 17554857.

de Azevedo WF, Dias R (December 2008). "Computational methods for calculation of ligand-binding affinity". Current Drug Targets. 9 (12): 1031–1039. doi:10.2174/138945008786949405. PMID 19128212.

Mauser H, Guba W (May 2008). "Recent developments in de novo design and scaffold hopping". Current Opinion in Drug Discovery & Development. 11 (3): 365–374. PMID 18428090.

Klebe G (2000). "Recent developments in structure-based drug design". Journal of Molecular Medicine. 78 (5): 269–281. doi:10.1007/s001090000084. PMID 10954199. S2CID 21314020.

Schneider G, Fechner U (August 2005). "Computer-based de novo design of drug-like molecules". Nature Reviews. Drug Discovery. 4 (8): 649–663. doi:10.1038/nrd1799. PMID 16056391. S2CID 2549851.

Leis S, Schneider S, Zacharias M (2010). "In silico prediction of binding sites on proteins". Current Medicinal Chemistry. 17 (15): 1550–1562. doi:10.2174/092986710790979944. PMID 20166931.

Liu J, Wang R (March 2015). "Classification of current scoring functions". Journal of Chemical Information and Modeling. 55 (3): 475–482. doi:10.1021/ci500731a. PMID 25647463.

Klein DF (March 2008). "The loss of serendipity in psychopharmacology". JAMA. 299 (9): 1063–1065. doi:10.1001/jama.299.9.1063. PMID 18319418.

ncbi.nlm.nih.gov

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Klebe G (2000). "Recent developments in structure-based drug design". Journal of Molecular Medicine. 78 (5): 269–281. doi:10.1007/s001090000084. PMID 10954199. S2CID 21314020.

Wang R, Gao Y, Lai L (2000). "LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design". Journal of Molecular Modeling. 6 (7–8): 498–516. doi:10.1007/s0089400060498. S2CID 59482623.

Schneider G, Fechner U (August 2005). "Computer-based de novo design of drug-like molecules". Nature Reviews. Drug Discovery. 4 (8): 649–663. doi:10.1038/nrd1799. PMID 16056391. S2CID 2549851.

Kotz J (April 2012). "Phenotypic screening, take two". Science-Business EXchange. 5 (15): 380. doi:10.1038/scibx.2012.380. ISSN 1945-3477. S2CID 72519717.

Drug design (English Wikipedia)

books.google.com (Global: 3^rd place; English: 3^rd place)

doi.org (Global: 2^nd place; English: 2^nd place)

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

jstor.org (Global: 26^th place; English: 20^th place)

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

scripps.edu (Global: low place; English: low place)

autodock.scripps.edu

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

ssrn.com (Global: 703^rd place; English: 501^st place)

papers.ssrn.com

upenn.edu (Global: 702^nd place; English: 520^th place)

repository.upenn.edu

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Drug design (English Wikipedia)

books.google.com (Global: 3rd place; English: 3rd place)

doi.org (Global: 2nd place; English: 2nd place)

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

jstor.org (Global: 26th place; English: 20th place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

scripps.edu (Global: low place; English: low place)

autodock.scripps.edu

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

ssrn.com (Global: 703rd place; English: 501st place)

papers.ssrn.com

upenn.edu (Global: 702nd place; English: 520th place)

repository.upenn.edu

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

books.google.com (Global: 3^rd place; English: 3^rd place)

doi.org (Global: 2^nd place; English: 2^nd place)

harvard.edu (Global: 18^th place; English: 17^th place)

jstor.org (Global: 26^th place; English: 20^th place)

nih.gov (Global: 4^th place; English: 4^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

ssrn.com (Global: 703^rd place; English: 501^st place)

upenn.edu (Global: 702^nd place; English: 520^th place)

worldcat.org (Global: 5^th place; English: 5^th place)